When was Elpiscience founded?

Elpiscience was founded in 2017 and raised its 1st funding round within a year of its incorporation.

Where is Elpiscience located?

Elpiscience is headquartered in Pudong, China.

How many employees does Elpiscience have?

As of Mar 31, 2026, the latest employee count at Elpiscience is 35.

Is Elpiscience a funded company?

Elpiscience is a funded company, having raised a total of $260M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on 2017.

When was the latest funding round of Elpiscience?

Elpiscience's latest funding was a $***** Series C round on May 13, 2021, with participation from 9 investors.

Where does Elpiscience rank among its competitors?

Elpiscience ranks 55th amongst 323 active competitors, of which 127 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Lyell Immunopharma, which secured $100M in Jul, 2025.

Who are the top competitors of Elpiscience?

Elpiscience's top competitors include Alector, Agios Pharmaceuticals and AnaptysBio. Among them, Lyell Immunopharma secured the most recent funding round in July, 2025.

Elpiscience - 2026 Company Profile, Team, Funding & Competitors

Elpiscience is a series C company based in Pudong (China), founded in 2017 by Hongtao Lu. It operates as a Developer of checkpoint inhibitors for the treatment of cancer. Elpiscience has raised $260M in funding from investors like CDH, Lilly Asia Ventures and Hyfinity Investments. The company has 323 active competitors, including 127 funded and 78 that have exited. Its top competitors include companies like Alector, Agios Pharmaceuticals and AnaptysBio.

Company Details

Elpiscience is developing immunotherapies for cancer. The company has its pipeline which includes in-house and partnership projects. The lead candidate, ES 101 is a bispecific antibody targeting 4-1BB and PD-L1 (preclinical stage). The molecule is developed by Inhibrx and the company has Chinese rights. Another candidate, ES001 is an anti-TIM-3 antibody, developed by Enumeral.

Website: www.elpiscience.com
Social
Phone Number: +86 **********

Key Metrics

Founded Year

2017

Location

Pudong, China

Stage

Series C

Total Funding

$260M in 4 rounds

Latest Funding Round

Series C, May 13, 2021, $*****

Investors

CDH & 14 more

Ranked

55^th among 323 active competitors

Employee Count

35 as on Mar 31, 2026

Similar Companies

Alector & 414 more

View Elpiscience's full profile

Elpiscience has raised a total funding of $260M over 4 rounds. Its first funding round was on 2017. Its latest funding round was a Series C round on May 13, 2021 for $*****. 9 investors participated in its latest round. Elpiscience has 15 institutional investors.

Here is the list of recent funding rounds of Elpiscience:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 13, 2021	6535320	Series C	9195412	5938072	7765593	8395853
Dec 29, 2019	7196694	Series B	1191549	7682641	5583007	Tencent & 9 more
Dec 03, 2018	3017603	Series A	2950924	3364736	Hillhouse	Lilly Asia Ventures & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Elpiscience's funding rounds and investors

The founders of Elpiscience is Hongtao Lu.

Here are the details of Elpiscience's key team members:

Hongtao Lu: Co-Founder & CSO of Elpiscience.
Contact Info: 1 email address

View details of Elpiscience's Founder profiles and Board Members

Elpiscience's employee count trend

Elpiscience has 35 employees as of Mar 26. Here is Elpiscience's employee count trend over the years:

Uncover Elpiscience's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Elpiscience include Alector, Agios Pharmaceuticals and AnaptysBio. Here is the list of Top 10 competitors of Elpiscience, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	73/100
2nd	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Third Rock Ventures ... & 6 others	70/100
3rd	AnaptysBio 2005, San Diego (United States), Public	Developer of immunology therapeutics for cancer and inflammatory diseases	$85.7M	BVF Partners, BioMedPartners & 12 others	69/100
4th	Hummingbird Bioscience 2015, Singapore (Singapore), Series C	Developer of antibody drugs for cancer treatment	$150M	OCTAVE Capital, GNTech Venture Capital & 23 others	67/100
5th	Lyell Immunopharma 2018, San Francisco (United States), Public	Developer of CAR- T therapy for cancer treatment	$493M	Sahsen Ventures, GSK & 5 others	66/100
6th	Imcheck Therapeutics 2015, Marseille (France), Acquired	Developer of immunotherapeutic antibodies for the treatment of multiple diseases	$185M	Life Sciences Partners, Pfizer & 16 others	66/100
7th	Beijing Jiakesi drug development 2015, Beijing (China), Public	Developer of small molecule based therapeutics for cancer treatment	$55M	Qiming Venture Partners, Lilly Asia Ventures ... & 3 others	65/100
8th	Boundless Bio 2018, San Diego (United States), Public	Developer of therapeutics for cancer by targeting ecDNA	$252M	RA Capital Management, Bayer & 19 others	65/100
9th	ABL Bio 2016, Seongnam-si (South Korea), Public	Bi-specific antibodies and Antibody-drug Conjugate immunotherapies for oncology and neurodegenerative diseases	$65M	QUAD, Hana Financial Group & 7 others	64/100
10th	Checkpoint Therapeutics 2014, New York City (United States), Acquired	Developer of immunotherapy and targeted cancer treatments to improve healthcare access	$58M	-	63/100
55th	Elpiscience 2017, Pudong (China), Series C	Developer of checkpoint inhibitors for the treatment of cancer	$260M	Tencent, Greater Bay Area Homeland Investments ... & 13 others	52/100